搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 24 小时
时间不限
过去 1 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
cancerhealth
1 小时
FDA Grants Accelerated Approval of Bizengri for Lung and Pancreatic Cancer
Zenocutuzumab, a bispecific antibody, is indicated for non-small-cell lung cancer and pancreatic adenocarcinoma with NRG1 ...
18 小时
Merus’ zenocutuzumab-zbco granted accelerated approval by FDA
On December 4, 2024, the Food and Drug Administration granted accelerated approval to Merus (MRUS)’ zenocutuzumab-zbco for adults with the ...
Medpage Today on MSN
16 小时
FDA OKs First Drug Targeting NRG1 Gene Fusion in Pancreatic, Lung Cancers
The approval stipulates use in advanced, unresectable, or metastatic disease that progressed on prior systemic therapy.
17 小时
Merus gets FDA approval of BIZENGRI in NRG1+ Pancreatic Adenocarcinoma, NSCLC
Merus (MRUS) announced that the FDA approved BIZENGRI(R) (zenocutuzumab-zbco), the first and only treatment indicated for ...
Cure Today
17 小时
FDA Approves Bizengri for Some with NSCLC, Pancreatic Adenocarcinoma
The FDA has approved the first systemic therapy for patients with NSCLC or pancreatic adenocarcinoma with an NRG1 gene fusion.
Medscape
4 小时
FDA Approves Bizengri for NSCLC and Pancreatic Cancers Harboring NRG1 Gene Fusion
The systemic agent is the first approved by the FDA for patients with NSCLC or pancreatic adenocarcinoma harboring an NRG1 gene fusion.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈